Amid the Rise of the Delta Variant, Here's My Top Coronavirus Vaccine Stock to Buy

Amid the Rise of the Delta Variant, Here's My Top Coronavirus Vaccine Stock to Buy
·4 min read

The first reason Pfizer is the best of the bunch is simply that it's the leader in the coronavirus vaccine market, at least in terms of revenue. The company also said that it expects roughly $33.5 billion in sales from BNT162b2 in 2021, which is much higher than the $26 billion Pfizer had projected in its first-quarter earnings release. Moderna (NASDAQ: MRNA) is the only rival that even comes close to Pfizer, with estimated sales of $19.2 billion for its vaccine, mRNA-1273 (this estimate will, in all likelihood, be revised upward).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting